LLY vs RMD

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...

ResMed Inc. (RMD) remains a robust, highly profitable, and well-managed global leader in sleep apnea and respiratory care. Its Q2 fiscal 2026 results showed healthy 11% YoY revenue growth and strong margins, with a very solid balance sheet. However, this analysis specifically targets '10x growth potential within the next 3-5 years.' Given RMD's current large-cap status ($32.64B), achieving a marke...